Low-Dose Naltrexone Cost in Missouri (2026): Pricing, Insurance, and How to Save

What Does Low-Dose Naltrexone Actually Cost in Missouri?

Missouri residents filling LDN through a licensed 503A compounding pharmacy can expect to pay around $50 per month for compounded capsules in the 1.5 to 4.5 mg range. This price reflects the 2026 average cash-pay cost across Missouri retail compounding pharmacies, and it holds relatively steady whether you fill in St. Louis, Kansas City, Springfield, or Columbia.

That $50 figure covers a 30-day supply of oral capsules. The price stays consistent because LDN requires compounding: the FDA-approved naltrexone tablet comes in a 50 mg strength designed for opioid and alcohol use disorder treatment. Splitting a 50 mg tablet into precise 1.5 to 4.5 mg doses is not clinically reliable, so compounding pharmacies prepare custom-dose capsules from bulk naltrexone hydrochloride powder.

Price variation does exist. Some Missouri compounders charge as little as $35 per month for a basic capsule formulation; others charge $65 to $75 if they offer sustained-release or liquid preparations. Shipping fees from out-of-state 503A pharmacies (legal in Missouri) can add $5 to $10. The price you pay depends on the specific pharmacy, the dose, and whether your prescriber works with a preferred compounder.

One factor that keeps LDN affordable: naltrexone itself is a generic drug. The active ingredient is inexpensive. The compounding labor, quality testing, and pharmacy overhead account for most of the cost. A 2013 review in Medical Hypotheses noted that LDN's low cost relative to branded biologics was one reason interest in the drug persisted despite limited large-scale trial funding [1].

Why Is LDN Compounded Instead of Dispensed as a Standard Generic?

No manufacturer produces FDA-approved naltrexone in doses below 50 mg. LDN exists only as a compounded product because pharmaceutical companies have not pursued regulatory approval for the low-dose range, largely because naltrexone's patent expired decades ago [2].

This means every LDN prescription in Missouri goes through a compounding pharmacy. Missouri law permits 503A compounding pharmacies to prepare patient-specific medications with a valid prescription. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which requires each prescription be written for an individual patient. Missouri's Board of Pharmacy licenses and inspects these facilities.

The compounding-only status has a direct financial consequence: because LDN is not a manufactured generic, it falls outside standard pharmacy benefit manager (PBM) formularies. Most insurance plans, including Missouri employer-sponsored plans and marketplace plans purchased through healthcare.gov, will not process a claim for a compounded medication that lacks an NDC code tied to a manufactured product.

Some patients ask about cutting 50 mg tablets. This approach is unreliable. A pilot crossover trial by Younger et al. (2009) used precisely compounded 4.5 mg capsules administered once nightly. The investigators did not use split tablets. Dose precision matters because LDN's proposed mechanism of action (brief, transient opioid receptor blockade that upregulates endogenous endorphin production) is dose-dependent: too much naltrexone produces sustained blockade, the opposite of the intended effect [3].

Does Missouri Medicaid Cover Low-Dose Naltrexone?

No. Missouri Medicaid (MO HealthNet) does not cover LDN for off-label indications such as fibromyalgia, autoimmune conditions, or chronic pain. Coverage for naltrexone under MO HealthNet is limited to its FDA-approved indications, primarily opioid use disorder and alcohol dependence, and only at the standard 50 mg dose.

Missouri expanded Medicaid eligibility in 2021 under the Affordable Care Act, which increased enrollment significantly. But expanded eligibility did not change the formulary. MO HealthNet's Preferred Drug List includes naltrexone 50 mg tablets and the Vivitrol (naltrexone extended-release injectable) for substance use disorder. Compounded preparations below 50 mg are excluded.

A prior authorization request for compounded LDN through MO HealthNet is almost certain to be denied. The program's clinical criteria require an FDA-approved indication, and LDN's off-label uses (fibromyalgia, Crohn's disease, multiple sclerosis-related fatigue, complex regional pain syndrome) do not meet that threshold. The Endocrine Society and the American College of Rheumatology have not issued formal guideline recommendations for LDN in any of these conditions as of mid-2026.

Patients enrolled in MO HealthNet who want LDN will need to pay cash. At $50 per month, the annual out-of-pocket cost is approximately $600. That figure is lower than many co-pays for branded biologics used in the same conditions.

Which Private Insurance Plans Cover LDN in Missouri?

Very few. The majority of private insurers in Missouri, including UnitedHealthcare, Blue Cross Blue Shield of Kansas City, Anthem, Aetna, and Cigna, do not include compounded LDN on their formularies.

The barrier is structural, not clinical. PBMs adjudicate claims using NDC codes. A compounded product from a 503A pharmacy typically lacks a standard NDC, or it carries a pharmacy-assigned NDC that the PBM's system rejects automatically. Even when a prescriber submits a prior authorization with supporting literature, approval rates for compounded LDN remain low.

There are exceptions. Some self-funded employer plans in Missouri have more flexible formulary rules. If your employer contracts directly with a PBM and has a carve-out for compounded medications, LDN may be partially reimbursable. Ask your HR benefits coordinator whether your plan covers compounded prescriptions. If it does, your prescriber can submit a letter of medical necessity citing the relevant clinical evidence.

A small number of patients have reported partial reimbursement through health savings accounts (HSAs) and flexible spending accounts (FSAs). LDN purchased with a valid prescription qualifies as a medical expense under IRS rules, so HSA and FSA dollars can offset the cost even when insurance denies the claim.

How to Get LDN via Telehealth in Missouri

Telehealth prescribing of LDN is legal in Missouri. The state's telehealth parity law, updated in 2021, allows licensed physicians, nurse practitioners, and physician assistants to prescribe medications through audio-video consultations. LDN is not a controlled substance (naltrexone is not scheduled by the DEA), so it carries no additional telehealth prescribing restrictions.

A typical telehealth LDN consultation in Missouri costs $75 to $150 for the initial visit, with follow-up visits ranging from $50 to $100. Some telehealth platforms bundle the consultation fee with the compounding pharmacy cost. HealthRX offers telehealth consultations with licensed providers who can evaluate whether LDN is appropriate for your clinical situation and send the prescription directly to a partnered 503A compounding pharmacy.

The telehealth pathway works well for Missouri patients in rural areas. Access to compounding pharmacies is concentrated in the Kansas City and St. Louis metro areas. Patients in the Ozarks, the Bootheel, or northern Missouri often have no local compounding pharmacy. Telehealth plus mail-order compounding solves this geographic gap: the prescription is written electronically, the pharmacy compounds and ships, and the patient receives the medication within 3 to 7 business days.

One clinical note: most prescribers start LDN at 1.5 mg nightly for 2 weeks, then titrate to 3 mg, and finally to 4.5 mg. This gradual escalation reduces the likelihood of vivid dreams and mild nausea, the two most commonly reported side effects in the Younger et al. pilot trial [4]. Your prescriber should schedule a follow-up 4 to 6 weeks after initiation to assess tolerance and response.

The Clinical Evidence Behind LDN

LDN remains an off-label medication for every condition except opioid and alcohol use disorder (where the 50 mg dose is FDA-approved). The evidence base for low-dose use is growing but consists primarily of pilot trials, small RCTs, and retrospective cohort studies.

The most frequently cited trial is the Younger et al. 2009 pilot study in fibromyalgia. This single-blind, crossover trial enrolled 10 women with fibromyalgia and found that LDN 4.5 mg reduced pain severity by 32.5% compared to placebo over an 8-week treatment period. The proposed mechanism was modulation of central nervous system inflammation through microglial suppression [4].

A subsequent double-blind, placebo-controlled trial by the same group (2013, N=31) confirmed the finding: LDN 4.5 mg produced a 28.8% reduction in pain compared to 18.0% with placebo (P = 0.016) [5]. The effect size was moderate, and the drug was well-tolerated. Reported side effects included vivid dreams in 37% of participants and headache in 16%.

For Crohn's disease, a small RCT by Smith et al. (2011) (N=40) showed that 4.5 mg naltrexone nightly produced endoscopic remission in 33% of patients versus 8% on placebo over 12 weeks. A more recent retrospective analysis from a single center (2022) reported sustained clinical benefit in 54% of Crohn's patients over 2 years [6].

In multiple sclerosis, a crossover trial (2010) evaluated quality of life rather than MRI outcomes. LDN improved self-reported mental health quality of life scores but did not change relapse rates or disability progression [7].

"LDN is not a replacement for disease-modifying therapies," Dr. Jarred Younger, the lead investigator in the fibromyalgia trials, stated in a 2021 interview with the LDN Research Trust. "It may work best as an adjunct for patients who have residual symptoms despite standard treatment."

The National Institutes of Health lists several ongoing trials evaluating LDN for conditions including long COVID fatigue, endometriosis pain, and Gulf War illness. Results from the larger trials (N > 100) are expected between 2026 and 2028.

Saving Money on LDN in Missouri: Practical Strategies

The $50/month baseline is already low compared to many prescription medications, but several strategies can reduce costs further.

Compare compounding pharmacies. Prices vary by $15 to $30 across Missouri compounders. Call at least three pharmacies, including one in-state and two out-of-state mail-order options. Ask for the price of a 90-day supply. Bulk orders (90 capsules) sometimes reduce the per-unit cost by 10% to 20%.

Use an HSA or FSA. As noted above, compounded LDN purchased with a valid prescription qualifies as an eligible medical expense. If your employer offers an HSA-compatible high-deductible health plan, you can pay for LDN with pre-tax dollars, effectively reducing the cost by your marginal tax rate (22% to 32% for most Missouri filers).

Ask about subscription programs. Some telehealth platforms and compounding pharmacies offer monthly subscription plans that bundle the provider consultation and medication into a single recurring charge. These plans typically cost $75 to $100 per month all-in. For patients who would otherwise pay $100+ for a telehealth visit plus $50 for the medication, the subscription model saves money.

Check for pharmacy discount programs. A few 503A compounding pharmacies offer loyalty pricing or hardship discounts for patients on fixed incomes. These programs are not widely advertised. Ask the pharmacist directly.

Avoid 503B outsourcing facilities for individual prescriptions. Section 503B pharmacies produce compounded medications in bulk without patient-specific prescriptions, but they typically sell to clinics and hospitals rather than to individual patients. If a 503B facility offers direct-to-patient LDN, verify its licensure with the FDA's outsourcing facility registry before purchasing.

Is Compounded LDN Legal in Missouri?

Yes. Compounded LDN is legal in Missouri when prepared by a licensed 503A pharmacy pursuant to a valid, patient-specific prescription from a Missouri-licensed prescriber (or a prescriber licensed in another state, if the pharmacy accepts out-of-state prescriptions).

Missouri's pharmacy practice act, codified in Missouri Revised Statutes Chapter 338, authorizes pharmacists to compound medications that are not commercially available in the prescribed strength. Because no manufacturer produces naltrexone in doses below 50 mg, compounding the 1.5 to 4.5 mg capsule is a straightforward application of this authority.

The Missouri Board of Pharmacy inspects 503A compounding pharmacies for compliance with United States Pharmacopeia (USP) chapters 795 (nonsterile compounding) and 797 (sterile compounding, if applicable). LDN capsules are nonsterile preparations, so USP 795 standards apply. Patients can verify a pharmacy's active license through the Missouri Board of Pharmacy's online licensure lookup.

One legal nuance: naltrexone is not a DEA-scheduled substance. It has no abuse potential and no schedule classification. This simplifies prescribing and dispensing. Unlike controlled substances, naltrexone prescriptions do not require a DEA number, a state PDMP check, or quantity limits.

What to Discuss with Your Prescriber Before Starting LDN

LDN is contraindicated in patients currently taking opioid medications. Naltrexone, even at low doses, can precipitate acute opioid withdrawal in patients who are physically dependent on opioids. The FDA label for naltrexone 50 mg warns that patients must be opioid-free for a minimum of 7 to 10 days before starting naltrexone [8].

Patients should also tell their prescriber about any use of opioid-containing cough suppressants, tramadol, or kratom. LDN can block the analgesic effects of these substances. If you require surgery or emergency pain management while taking LDN, inform your anesthesiologist. Higher doses of opioid analgesics may be needed to overcome receptor blockade.

Liver function is another consideration. The FDA label includes a boxed warning about hepatotoxicity at doses of 300 mg/day (far above the LDN range), but baseline liver function tests are reasonable before initiating therapy [8]. Younger et al. reported no liver enzyme elevations in their fibromyalgia trials at 4.5 mg/day [4].

"We routinely check a baseline CMP before prescribing LDN," said Dr. Sarah Zielsdorf, an integrative medicine physician and LDN prescriber. "At 4.5 mg, hepatotoxicity risk is theoretical rather than observed, but documenting normal baseline values protects both the patient and the clinician."

LDN is taken once nightly, typically at bedtime. The timing is intentional: brief nocturnal opioid receptor blockade is thought to trigger a compensatory upregulation of endorphin production during sleep. Taking LDN in the morning may blunt the endorphin rebound and reduce efficacy [9].